Stephen M. Kaufhold active positions
| Companies | Position | Start | End |
|---|---|---|---|
| VITAE PHARMACEUTICALS INC | Treasurer | 2016-10-24 | - |
Career history of Stephen M. Kaufhold
Former positions of Stephen M. Kaufhold
| Companies | Position | Start | End |
|---|---|---|---|
Allergan GI Corp.
 Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Treasurer | - | - |
| TOBIRA THERAPEUTICS INC | Director of Finance/CFO | 2016-10-30 | - |
| Treasurer | 2016-10-30 | - |
Statistics
International
| United States | 4 |
Operational
| Treasurer | 3 |
| Director of Finance/CFO | 1 |
Sectoral
| Health Technology | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
Vitae Pharmaceuticals LLC
 Vitae Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vitae Pharmaceuticals LLC is a clinical-stage bio-pharmaceutical company, which engages in discovering and developing novel, small molecule drugs for diseases, including chronic kidney disease, diabetes and Alzheimer's disease, and autoimmune disorders, acute coronary syndrome, and immuno-oncology. The company was founded by John J. Baldwin, Bartosz A. Grzybowski, George M. Whitesides, and Eugene Shakhnovich on May 21, 2001 and is headquartered in Fort Washington, PA. | Health Technology |
Tobira Therapeutics, Inc.
 Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on September 11, 2006 and is headquartered in Madison, NJ. | Health Technology |
Allergan GI Corp.
Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Health Technology |
- Stock Market
- Insiders
- Stephen M. Kaufhold
- Experience
